

*Article*

# Differential Response Following Infection of Mouse CNS with Virulent and Attenuated Vaccinia Virus Strains

**Tomer Israely <sup>1,†</sup>, Nir Paran <sup>1,†</sup>, Noam Erez <sup>1</sup>, Lilach Cherry <sup>1</sup>, Hadas Tamir <sup>1</sup>, Hagit Achdout <sup>1</sup>, Boaz Politi <sup>1</sup>, Ofir Israeli <sup>2</sup>, Galia Zaide <sup>2</sup>, Inbar Cohen-Gihon <sup>2</sup>, Einat B. Vitner <sup>1</sup>, Shlomo Lustig <sup>1</sup> and Sharon Melamed <sup>1,\*</sup>**

<sup>1</sup> Department of Infectious Diseases, Israel Institute of Biological Research (IIBR), Ness-Ziona, Israel; tomeri@iibr.gov.il (T.I.); nirp@iibr.gov.il (N.P.); noame@iibr.gov.il (N.E.); lilachc@iibr.gov.il (L.C.); hadast@iibr.gov.il (H.T.); hagita@iibr.gov.il (H.A.); boazp@iibr.gov.il (B.P.); einatv@iibr.gov.il (E.B.V.); shlomolustig@gmail.com (S.L.)

<sup>2</sup> Department of Biochemistry and Molecular Genetics, Israel Institute of Biological Research (IIBR), Ness-Ziona, Israel; ofiri@iibr.gov.il (O.I.); galiaz@iibr.gov.il (G.Z.); inbarg@iibr.gov.il (I.C.-G.)

<sup>†</sup> Authors contributed equally to the article

\* Correspondence: sharonm@iibr.gov.il; Tel.: +972-9-9381646

## Supplementary Materials

**Table S1.** Selected early (2 d.p.i.) and late (4–5 d.p.i.) differentiating genes used for quantitative real-time RT-PCR.

Gene#	Early (2 d.p.i.)	Gene #	Late (4–5 d.p.i.)
1	Ifi44-Mm00505670_m1	1	Cd3d-Mm00442746_m1
2	Irf7-Mm00516793_g1	2	Cd3e-Mm01179194_m1
3	Ifi27l2a-Mm01329883_gH	3	Cd8a-Mm01182107_g1
4	Ifit1-Mm00515153_m1	4	Cd8b1-Mm00438116_m1
5	Isg15-Mm01705338_s1	5	Cd27-Mm01185212_g1
6	Slfn1-Mm00488306_m1	6	Cxcr3-Mm99999054_s1
7	Rtp4-Mm00469759_m1	7	Foxp3-Mm00475162_m1
8	Ifit3-Mm01704846_s1	8	Gimap7-Mm00525315_m1
9	Zbp1-Mm01247052_m1	9	Ncr1-Mm01337324_g1
10	Cxcl10-Mm00445235_m1	10	Ptprcap-Mm01236556_m1
11	Ms4a6c-Mm00459296_m1	11	Sh2d1a-Mm01316997_m1

12	Slfn4-Mm01298330_m1	12	Il11-Mm00434162_m1
13	18S-Hs99999901_s1	13	Mmp3-Mm00440295_m1
		14	Mmp8-Mm00439509_m1
		15	Slc10a6-Mm00512730_m1
		16	Timp1-Mm01341360_g1
		17	Trem1-Mm01278455_m1
		18	Cxcl2-Mm00436450_m1
		19	Cxcr2-Mm99999117_s1
		20	18S-Hs99999901_s1

**Table S2.** Significant brain gene expression level following VACV infection (corresponding to Table 3).

Gene	p value			
	Day 4 p.i.		Day 5 p.i.	
	Wyeth	WR	Wyeth	WR
<i>C1ra</i>	6.5E-58	6.6E-07	1.2E-19	1.1E-46
<i>C1rb</i>	1.1E-07	6.9E-03	3.3E-05	5.7E-05
<i>C1s</i>	1.6E-87	6.0E-07	6.6E-102	4.8E-65
<i>C2</i>	1.4E-51	2.3E-03	8.7E-13	1.8E-26
<i>C3</i>	7.6E-30	3.6E-09	5.4E-32	1.2E-139
<i>C6</i>	1.6E-05	4.7E-01	1.1E-02	7.4E-02
<i>H2-Aa</i>	6.7E-67	4.0E-04	6.6E-80	5.4E-65
<i>H2-Eb1</i>	3.3E-140	3.2E-03	5.1E-57	2.7E-61
<i>H2-K1</i>	2.1E-284	2.4E-14	1.7E-130	6.7E-199
<i>Cd3d</i>	2.7E-17	2.1E-01	1.3E-27	5.0E-05
<i>Cd3e</i>	2.9E-22	1.0E-02	4.8E-36	4.6E-09
<i>Cd3g</i>	4.1E-17	2.4E-01	3.4E-32	8.4E-06
<i>Cd8a</i>	4.6E-25	9.3E-02	1.1E-44	3.1E-09
<i>Cd8b1</i>	7.2E-14	1.6E-01	1.2E-40	1.1E-04
<i>Cd2</i>	1.4E-17	7.0E-01	1.3E-28	9.0E-07
<i>Cd27</i>	5.5E-16	8.0E-01	2.4E-22	1.7E-03
<i>Cd5</i>	9.6E-05	2.1E-01	9.8E-21	4.6E-01
<i>Ccl2</i>	3.3E-68	3.8E-21	5.1E-14	8.5E-80
<i>Ccl4</i>	3.0E-19	NA	5.6E-10	1.4E-32
<i>Ccl5</i>	3.6E-41	2.3E-09	4.7E-74	3.4E-23
<i>Ccl7</i>	4.1E-37	2.4E-08	2.2E-22	3.5E-42


<i>Ccl8</i>	9.5E-21	1.7E-02	3.0E-28	1.4E-09
<i>Ccl12</i>	1.2E-64	6.1E-19	1.2E-15	5.9E-18
<i>Ccl19</i>	2.7E-11	6.4E-01	1.8E-11	2.0E-03
<i>Mki67</i>	7.3E-27	9.0E-02	8.8E-83	6.1E-19
<i>CD40</i>	3.9E-11	6.1E-01	3.0E-12	9.7E-06
<i>Tmem119</i>	4.4E-22	8.7E-01	9.7E-17	5.2E-01
<i>Cx3cr1</i>	1.8E-01	1.1E-02	7.4E-02	5.6E-25
<i>Prf1</i>	5.2E-21	6.3E-01	6.92E-22	4.07E-19
<i>Gzma</i>	2.3E-42	2.2E-06	1.07E-45	8.17E-29
<i>Gzmb</i>	2.0E-55	3.6E-04	2.39E-48	1.25E-55
<i>Mmp3</i>	2.6E-03	1.1E-17	5.0E-01	8.7E-22
<i>Mmp8</i>	1.0E-01	1.3E-04	4.2E-02	1.3E-21
<i>Mmp13</i>	5.0E-01	8.2E-04	1.0E-01	8.5E-06
<i>Mmp19</i>	1.5E-05	2.0E-09	2.8E-06	1.5E-42
<i>Timp1</i>	4.1E-18	1.1E-22	3.1E-15	1.1E-95


**Figure S1.** Top canonical pathways following infection with VACV-Wyeth and VACV-WR. IPA analysis of brain gene expression 2, 4 and 5 d.p.i with VACV-Wyeth (106 pfu) and VACV-WR (100pfu). Shared pathways are color coded respectively.

No.	VACV-Wyeth (p-values)			No.	VACV-WR (p-values)			#	Canonical Pathway	Day2	Day4	Day5
	#	Canonical Pathway	Day2		#	Canonical Pathway	Day2		Canonical Pathway	Day2	Day4	Day5
1		Th1 and Th2 Activation Pathway	0.5	23.0	34.4	1	Hepatic Fibrosis / Hepatic Stellate Cell Activation	0.5		19.6	23.0	
2		Th1 Pathway	0.5	16.7	30.2	2	Granulocyte Adhesion and Diapedesis	0.0		13.9	19.2	
3		T Helper Cell Differentiation	1.9	16.3	28.5	3	Role of Macrophages Fibroblasts and Endothelial Cells in Rheumatoid Arthritis	1.4		11.4	20.0	
4		Type I Diabetes Mellitus Signaling	2.3	15.2	24.1	4	Atherosclerosis Signaling	0.0		12.6	19.5	
5		Th2 Pathway	0.5	16.3	24.3	5	Acute Phase Response Signaling	1.3		14.0	16.4	
6		TREM1 Signaling	0.0	14.4	24.7	6	Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	0.5		9.4	19.0	
7		Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	2.4	16.2	20.5	7	Agranulocyte Adhesion and Diapedesis	0.0		14.2	14.4	
8		Role of Macrophages Fibroblasts and Endothelial Cells in Rheumatoid Arthritis	2.7	13.1	22.3	8	Dendritic Cell Maturation	0.6		8.1	17.1	
9		Altered T Cell and B Cell Signaling in Rheumatoid Arthritis	0.5	13.2	24.2	9	Type I Diabetes Mellitus Signaling	0.0		7.0	17.8	
10		iCOS-iCOSL Signaling in T Helper Cells	1.1	14.5	21.6	10	Th1 Pathway	0.0		7.1	16.5	


11	Dendritic Cell Maturation	2.7	13.1	20.3	11	Colorectal Cancer Metastasis Signaling	2.8	6.6	13.9
12	Acute Phase Response Signaling	2.5	14.9	16.4	12	Th1 and Th2 Activation Pathway	0.0	5.8	17.3
13	Hepatic Fibrosis / Hepatic Stellate Cell Activation	2.4	11.2	18.4	13	Glucocorticoid Receptor Signaling	7.5	6.2	9.2
14	EIF2 Signaling	18.8	12.8	0.0	14	Role of Osteoblasts Osteoclasts and Chondrocytes in Rheumatoid Arthritis	1.0	6.4	14.4
15	CD28 Signaling in T Helper Cells	1.4	12.4	17.5	15	Axonal Guidance Signaling	5.9	6.0	9.6
16	Role of NFAT in Regulation of the Immune Response	2.6	13.1	15.4	16	LXR/RXR Activation	0.0	8.7	12.8
17	Antigen Presentation Pathway	6.3	9.7	14.9	17	TREM1 Signaling	0.0	5.1	15.9
18	PKC $\theta$ Signaling in T Lymphocytes	1.8	11.7	15.8	18	IL-8 Signaling	4.6	3.5	12.7
19	Crosstalk between Dendritic Cells and Natural Killer Cells	0.5	11.6	17.1	19	IL-10 Signaling	1.0	7.1	12.0
20	Death Receptor Signaling	2.3	9.5	16.3	20	Molecular Mechanisms of Cancer	6.7	3.0	10.4
21	Communication between Innate and Adaptive Immune Cells	0.0	10.7	17.0	21	T Helper Cell Differentiation	0.0	4.8	15.1
22	IL-10 Signaling	2.1	12.5	12.1	22	NF- $\kappa$ B Signaling	2.5	4.1	12.7
23	Tec Kinase Signaling	1.4	9.4	15.1	23	Production of Nitric Oxide and Reactive Oxygen Species in Macrophages	1.8	6.3	11.2
24	Granulocyte Adhesion and Diapedesis	0.0	10.5	15.3	24	Osteoarthritis Pathway	1.7	6.5	10.7
25	Atherosclerosis Signaling	0.3	10.1	15.1	25	Altered T Cell and B Cell Signaling in Rheumatoid Arthritis	0.0	3.1	15.6
26	T Cell Receptor Signaling	1.5	11.0	12.9	26	Antigen Presentation Pathway	0.3	7.8	10.5
27	IL-6 Signaling	2.0	8.6	14.0	27	Th2 Pathway	0.3	3.7	14.2
28	Phagosome Formation	1.4	9.7	13.2	28	EIF2 Signaling	18.1	0.0	0.0
29	NF- $\kappa$ B Signaling	2.0	7.9	13.9	29	IL-6 Signaling	0.9	6.3	10.5
30	PI3K Signaling in B Lymphocytes	2.7	10.6	10.3	30	Leukocyte Extravasation Signaling	1.5	6.9	9.2
31	Interferon Signaling	5.3	7.5	10.9	31	Phagosome Formation	0.9	3.9	11.8
32	Graft-versus-Host Disease Signaling	1.1	9.4	12.4	32	Death Receptor Signaling	0.3	5.7	10.1
33	Production of Nitric Oxide and Reactive Oxygen Species in Macrophages	1.8	8.5	11.9	33	Communication between Innate and Adaptive Immune Cells	0.0	2.4	13.6
34	Toll-like Receptor Signaling	1.4	8.2	12.6	34	iCOS-iCOSL Signaling in T Helper Cells	0.7	1.5	13.5


**Figure S2.** Antigen Presentation Pathway. Genes associated with antigen presentation following infection with (A) VACV-Wyeth ( $-\log(p\text{-values})$ : 6.3) and (B) VACV-WR 2 d.p.i. ( $-\log(p\text{-values})$ : 0.3). Differentially expressed genes are highlighted in color. Color intensity indicates the degree of up regulation (red) or down-regulation (green) relative to the day 2 mock infected brains. Solid lines represent direct interactions. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).





**Figure S3.** Mitochondrial Dysfunction Pathway. Genes associated with mitochondrial dysfunction following infection with (A) VACV-Wyeth (-log(*p*-values): 6.6) and (B) VACV-WR 2 d.p.i. (-log(*p*-values): 13.7). Differentially expressed genes are highlighted in color. Color intensity indicates the degree of up regulation (red) or down-regulation (green) relative to the day 2 mock infected brains. Solid lines represent direct interactions and dashed lines represent indirect interactions. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).





**Figure S4.** Oxidative Phosphorylation Pathway. Genes associated with oxidative phosphorylation following infection with (A) VACV-Wyeth (-log(*p*-values): 7.0) and (B) VACV-WR 2 d.p.i. (-log(*p*-values): 14.2). Differentially expressed genes are highlighted in color. Color intensity indicates the degree of up regulation (red) or down-regulation (green) relative to the day 2 mock infected brains. Solid lines represent direct interactions and dashed lines represent indirect interactions. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).

